The CD155 antibody market is booming, projected to reach $1 billion by 2033 with a CAGR of 11.9%. Driven by advancements in antibody engineering and rising disease prevalence, key players like Sino Biological and Abcam dominate this rapidly expanding sector. Explore market trends and insights now.
We do not share your information with anyone. However, we may send you emails based on your report interest from time to time. You may contact us at any time to opt-out.
